ANIP

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.03
Percentage change 0.05	%

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI CALF IWM VXF IJT SPSM PJP IWO SLYG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	17.21%	Shs Outstand	21.07M	Perf Week	-0.67%
Market Cap	1.19B	Forward P/E	10.35	EPS next Y	5.47	Insider Trans	-4.29%	Shs Float	17.41M	Perf Month	-5.42%
Income	-10.52M	PEG	-	EPS next Q	1.45	Inst Own	91.59%	Short Float	10.57%	Perf Quarter	0.69%
Sales	555.46M	P/S	2.14	EPS this Y	6.51%	Inst Trans	26.41%	Short Ratio	6.62	Perf Half Y	-9.63%
Book/sh	19.26	P/B	2.94	EPS next Y	8.97%	ROA	-0.82%	Short Interest	1.84M	Perf Year	7.61%
Cash/sh	7.29	P/C	7.77	EPS next 5Y	2.20%	ROE	-2.13%	52W Range	51.24 - 70.81	Perf YTD	2.63%
Dividend Est.	-	P/FCF	15.64	EPS past 5Y	-6.27%	ROI	-1.00%	52W High	-20.08%	Beta	0.73
Dividend TTM	-	Quick Ratio	1.96	Sales past 5Y	21.46%	Gross Margin	48.93%	52W Low	10.44%	ATR (14)	2.10
Dividend Ex-Date	-	Current Ratio	2.74	EPS Y/Y TTM	-186.25%	Oper. Margin	1.73%	RSI (14)	45.77	Volatility	3.98% 3.61%
Employees	642	Debt/Eq	1.60	Sales Y/Y TTM	23.60%	Profit Margin	-1.89%	Recom	1.50	Target Price	78.67
Option/Short	Yes / Yes	LT Debt/Eq	1.58	EPS Q/Q	-354.02%	Payout	0.00%	Rel Volume	0.83	Prev Close	56.56
Sales Surprise	2.74%	EPS Surprise	23.39%	Sales Q/Q	12.52%	Earnings	Nov 08 BMO	Avg Volume	277.79K	Price	56.59
SMA20	-0.94%	SMA50	-2.40%	SMA200	-8.86%	Trades		Volume	229,634	Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60
Aug-05-15	Reiterated	Oppenheimer	Outperform	$74 → $65
Aug-04-15	Reiterated	ROTH Capital	Neutral	$70 → $67
Jul-31-15	Reiterated	Oppenheimer	Outperform	$72 → $74

Show Previous Ratings

Dec-02-24 02:21PM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Nov-26-24 04:30PM	ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
09:55AM	Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-24 12:00PM	ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-14-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
04:00AM	Loading…
Nov-09-24 04:00AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-08-24 10:00AM	Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics (Zacks) +5.24%
08:21AM	ANI Pharma Boosts FY24 Outlook As Q3 Results Top Estimates - Update (RTT News)
08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates (Zacks)
06:58AM	ANI: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Nov-07-24 07:06AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-24 04:30PM	ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Nov-01-24 10:00AM	Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline (Zacks)
Oct-30-24 05:00PM	ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET (GlobeNewswire)
06:50AM	Loading…
Oct-25-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% (GlobeNewswire)
Oct-24-24 06:50AM	ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks)
Oct-21-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Oct-15-24 12:10PM	Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-11-24 01:40PM	ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential (Benzinga)
Oct-09-24 09:55AM	Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know (Zacks)
Sep-27-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
Sep-26-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% (GlobeNewswire)
Sep-16-24 08:53AM	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences (GlobeNewswire)
06:50AM	ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences (GlobeNewswire)
Sep-13-24 06:50AM	ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution (GlobeNewswire)
Sep-11-24 06:50AM	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger (Business Wire)
Sep-10-24 02:09PM	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences (GlobeNewswire) -5.13%
09:00AM	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement (Business Wire)
12:15PM	Loading…
Aug-28-24 12:15PM	ANI Pharmaceuticals, Inc. (ANIP): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-15-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Aug-13-24 04:05PM	ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes (GlobeNewswire)
Aug-07-24 09:44PM	ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering (GlobeNewswire) -9.92%
07:00AM	ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Aug-06-24 10:00AM	Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics (Zacks) +6.98%
08:05AM	ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:58AM	ANI: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Aug-05-24 09:16AM	Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-31-24 07:00AM	ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET (GlobeNewswire)
Jul-15-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder (GlobeNewswire)
Jul-02-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP (GlobeNewswire)
Jun-25-24 07:00AM	ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year 2024 New Jersey Award Winner (GlobeNewswire)
Jun-24-24 11:28AM	Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal (Benzinga) +7.33%
11:14AM	Alimera Sciences shares jump by 77% after being acquired by ANI (Pharmaceutical Technology)
06:50AM	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences (GlobeNewswire)
Jun-13-24 08:53AM	Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options (Zacks)
Jun-06-24 01:00PM	Insider Sale: SVP & CFO Stephen Carey Sells 5,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-29-24 04:30PM	ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-24 10:52AM	ANI Pharmaceuticals Launches Kionex Suspension (MT Newswires)
09:35AM	Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Kionex Suspension (GlobeNewswire)
May-18-24 02:33AM	Director Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-16-24 07:00PM	Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
05:08PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing (MT Newswires)
May-13-24 03:03AM	ANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 01:48PM	ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations (GuruFocus.com)
11:54AM	ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:26AM	ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance (MT Newswires)
06:58AM	ANI: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
May-09-24 08:46AM	Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP) (Zacks)
May-06-24 11:26AM	ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store? (Zacks)
May-03-24 05:51PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing (MT Newswires)
10:00AM	ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
May-01-24 04:30PM	ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences (GlobeNewswire)
Apr-18-24 04:05PM	ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET (GlobeNewswire)
Apr-15-24 12:10PM	Why ANI (ANIP) is Poised to Beat Earnings Estimates Again (Zacks)
Apr-10-24 06:15PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know (Zacks)
Apr-09-24 06:50AM	ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension (GlobeNewswire)
Apr-05-24 09:30AM	Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It? (Zacks)
Apr-04-24 06:50AM	ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis (GlobeNewswire)
Apr-03-24 06:50AM	ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Apr-02-24 06:15PM	ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know (Zacks)
Mar-27-24 06:15PM	ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP (GlobeNewswire)
Mar-26-24 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-22-24 09:54PM	NYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-21-24 06:00PM	ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-20-24 09:30AM	ANI (ANIP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-19-24 06:15PM	ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know (Zacks)
Mar-14-24 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-08-24 11:54PM	ANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 Shares (GuruFocus.com)
Mar-06-24 11:29PM	Director Antonio Pera Sells 7,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
12:00PM	What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 09:30AM	Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest? (Zacks)
09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
08:35AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:27AM	Q4 2023 ANI Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 09:30AM	Compared to Estimates, ANI (ANIP) Q4 Earnings: A Look at Key Metrics (Zacks) +12.26%
07:56AM	ANI Pharmaceuticals Q4 Profit Tops Estimates; Revenues Up 39.7% (RTT News)
07:15AM	ANI: Q4 Earnings Snapshot (Associated Press Finance)
07:11AM	ANI Pharmaceuticals Inc (ANIP) Reports Strong Growth in Q4 and Full-Year 2023, Sets Positive ... (GuruFocus.com)
06:50AM	ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance (GlobeNewswire)
Feb-28-24 10:30AM	13 Stocks That Will Double in 2024 (Insider Monkey)
Feb-26-24 09:15AM	Unveiling ANI (ANIP) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis Krista	SVP, CHIEF HR OFFICER	Dec 11 '24	Sale	60.00	1,000	60,000	49,059	Dec 12 05:08 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Option Exercise	29.00	30,000	870,000	403,859	Nov 27 05:38 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Sale	57.99	33,481	1,941,442	370,378	Nov 27 05:38 PM
Lalwani Nikhil	Officer	Nov 26 '24	Proposed Sale	57.99	33,481	1,941,484		Nov 26 07:44 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 15 '24	Sale	57.70	6,500	375,050	76,777	Nov 18 04:03 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '24	Sale	61.36	250	15,340	56,238	Nov 14 04:16 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 14 '24	Sale	57.19	250	14,298	56,488	Oct 15 05:57 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 13 '24	Sale	56.82	250	14,205	56,738	Sep 16 04:50 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '24	Sale	59.62	250	14,905	56,988	Aug 14 08:29 AM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 18 '24	Sale	62.00	2,743	170,066	632,620	Jul 19 05:30 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 16 '24	Sale	64.27	22,000	1,413,940	649,620	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 17 '24	Sale	63.16	14,257	900,472	635,363	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 15 '24	Sale	63.38	11,000	697,180	671,620	Jul 17 07:07 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 12 '24	Sale	64.91	250	16,228	58,981	Jul 15 04:38 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jul 01 '24	Sale	63.44	20,000	1,268,800	193,226	Jul 02 08:58 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 21 '24	Sale	58.90	20,000	1,178,000	682,620	Jun 24 04:12 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 20 '24	Sale	59.86	11,447	685,217	702,620	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 18 '24	Sale	60.76	10,607	644,481	714,067	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 17 '24	Sale	61.41	7,946	487,964	724,674	Jun 20 07:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '24	Sale	63.80	250	15,950	59,231	Jun 14 05:23 PM
Marken James G.	SVP OPS & PROD DEV	Jun 07 '24	Option Exercise	52.70	12,550	661,366	128,916	Jun 11 04:51 PM
Gutwerg Ori	SVP, GENERICS	Jun 05 '24	Sale	67.00	2,985	199,995	77,227	Jun 06 06:21 PM
CAREY STEPHEN P.	SVP & CFO	Jun 04 '24	Sale	63.58	5,000	317,900	161,968	Jun 06 07:34 AM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jun 03 '24	Sale	64.41	20,000	1,288,200	213,226	Jun 04 06:08 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 21 '24	Sale	61.61	2,000	123,220	83,277	May 22 06:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 20 '24	Sale	61.81	12,855	794,568	732,620	May 21 05:21 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 16 '24	Sale	63.84	16,459	1,050,743	751,311	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 15 '24	Sale	65.86	14,850	978,021	767,770	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 17 '24	Sale	62.09	5,836	362,357	745,475	May 17 06:05 PM
TANNENBAUM RENEE P	Director	May 16 '24	Sale	63.87	2,000	127,740	18,211	May 17 06:01 PM
Lalwani Nikhil	PRESIDENT & CEO	May 14 '24	Sale	66.10	16,669	1,101,821	377,505	May 16 05:02 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '24	Sale	67.69	250	16,922	59,481	May 13 05:25 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	May 01 '24	Sale	66.62	20,000	1,332,400	233,226	May 03 05:48 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 19 '24	Sale	65.17	16,809	1,095,443	782,620	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 18 '24	Sale	64.98	10,423	677,287	799,429	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 17 '24	Sale	65.40	9,520	622,608	809,852	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 15 '24	Sale	66.33	7,414	491,771	825,206	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 16 '24	Sale	66.20	5,834	386,211	819,372	Apr 17 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 12 '24	Sale	67.79	250	16,948	59,731	Apr 15 06:28 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Apr 01 '24	Sale	67.25	20,000	1,345,000	253,226	Apr 02 06:59 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '24	Sale	66.54	250	16,635	59,981	Mar 13 04:48 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Mar 11 '24	Sale	65.81	20,000	1,316,200	273,226	Mar 13 04:44 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 08 '24	Sale	67.17	10,000	671,700	832,620	Mar 11 06:43 PM
CAREY STEPHEN P.	SVP & CFO	Mar 11 '24	Sale	65.55	7,787	510,438	177,712	Mar 11 06:39 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 06 '24	Sale	65.52	28,965	1,897,787	444,981	Mar 08 07:25 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 08 '24	Sale	67.13	16,292	1,093,682	411,629	Mar 08 07:25 PM
Marken James G.	SVP OPS & PROD DEV	Mar 07 '24	Sale	66.37	24,338	1,615,313	124,492	Mar 07 09:42 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 07 '24	Sale	66.35	15,085	1,000,890	842,620	Mar 07 09:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 06 '24	Sale	65.47	14,822	970,396	857,705	Mar 07 09:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 05 '24	Sale	65.35	10,093	659,578	872,527	Mar 07 09:11 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 05 '24	Sale	66.00	5,000	330,000	87,387	Mar 06 04:24 PM
Pera Antonio R	Director	Mar 04 '24	Sale	65.20	7,000	456,400	26,627	Mar 06 04:20 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '24	Sale	56.04	250	14,010	36,799	Feb 13 08:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 23 '24	Sale	56.44	15,000	846,600	882,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 22 '24	Sale	55.95	5,692	318,467	897,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 19 '24	Sale	55.57	4,524	251,399	903,312	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 17 '24	Sale	55.11	10,000	551,100	917,620	Jan 18 06:20 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 18 '24	Sale	55.30	9,784	541,055	907,836	Jan 18 06:20 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 16 '24	Sale	55.63	5,000	278,150	927,620	Jan 18 06:20 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 12 '24	Sale	56.43	250	14,108	37,049	Jan 16 09:09 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Dec 19 '23	Sale	52.65	25,000	1,316,250	932,620	Dec 19 05:44 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Dec 18 '23	Sale	52.44	13,026	683,083	957,620	Dec 19 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANI Pharmaceuticals Inc

Upgrade your FINVIZ experience